ACE inhibitory peptide KYIPIQ derived from yak milk casein induces nitric oxide production in HUVECs and diffuses via a transcellular mechanism in Caco-2 monolayers

[Display omitted] The purpose of this study was to explore the effects of KYIPIQ, an angiotensin I-converting enzyme (ACE) inhibitory peptide found in yak milk casein, on the production of nitric oxide (NO) in human vascular endothelial cells (HUVECs). Additionally, we also sought to study the trans...

Full description

Saved in:
Bibliographic Details
Published in:Process biochemistry (1991) 2020-12, Vol.99, p.103-111
Main Authors: Lin, Kai, Ma, Zhao, Ramachandran, Mythili, De Souza, Cristabelle, Han, Xue, Zhang, Lan-wei
Format: Article
Language:English
Subjects:
ACE inhibitory peptide
Adenocarcinoma
AKT protein
Angiotensin
Angiotensin I
Casein
Chemical compounds
Endothelial cells
Endothelial nitric oxide synthase
Hypertension
Kinases
Milk
Monolayers
Nitric oxide
Nitric-oxide synthase
Peptides
Peptidyl-dipeptidase A
Pharmacology
Phosphorylation
Transport mechanism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] The purpose of this study was to explore the effects of KYIPIQ, an angiotensin I-converting enzyme (ACE) inhibitory peptide found in yak milk casein, on the production of nitric oxide (NO) in human vascular endothelial cells (HUVECs). Additionally, we also sought to study the transport pathway of this peptide across monolayers of the human epithelial colorectal adenocarcinoma cell line (Caco-2). Treatment with peptide KYIPIQ increased NO synthesis and expression of phosphorylated endothelial nitric oxide synthase (eNOS) in HUVECs. Our results demonstrate that KYIPIQ-induced eNOS phosphorylation is dependent on the protein kinase B (Akt) activation pathway. Furthermore, our data indicate that the peptide KYIPIQ can be transported across the Caco-2 cell monolayer and that paracellular transport is the main transcellular mechanism. Thus, our studies suggest that KYIPIQ can be potentially used as a therapeutic agent for the treatment of hypertension.
ISSN:1359-5113
1873-3298
DOI:10.1016/j.procbio.2020.08.031